Relay Therapeutics (NASDAQ:RLAY) Stock Rating Upgraded by Zacks Research

Relay Therapeutics (NASDAQ:RLAY) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Thursday,Zacks.com reports.

Other equities research analysts have also issued research reports about the stock. Oppenheimer raised their price target on shares of Relay Therapeutics from $14.00 to $18.00 and gave the stock an “outperform” rating in a report on Tuesday, April 28th. UBS Group set a $26.00 price objective on shares of Relay Therapeutics in a research note on Tuesday, May 19th. HC Wainwright increased their target price on shares of Relay Therapeutics from $28.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday. Wells Fargo & Company raised their target price on Relay Therapeutics from $17.00 to $21.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 28th. Finally, The Goldman Sachs Group raised their target price on Relay Therapeutics from $22.00 to $31.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $25.92.

Relay Therapeutics Stock Performance

Shares of Relay Therapeutics stock opened at $19.44 on Thursday. Relay Therapeutics has a 52-week low of $3.43 and a 52-week high of $21.27. The stock has a market capitalization of $4.26 billion, a price-to-earnings ratio of -12.38 and a beta of 1.69. The company’s 50 day moving average price is $18.86 and its 200-day moving average price is $14.35.

Relay Therapeutics (NASDAQ:RLAY) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). The company had revenue of $0.35 million for the quarter, compared to the consensus estimate of $0.96 million. As a group, equities research analysts forecast that Relay Therapeutics will post -1.6 earnings per share for the current fiscal year.

Insider Transactions at Relay Therapeutics

In other news, insider Peter Rahmer sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $19.09, for a total value of $954,500.00. Following the completion of the transaction, the insider owned 225,857 shares in the company, valued at $4,311,610.13. This trade represents a 18.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Thomas Catinazzo sold 187,163 shares of Relay Therapeutics stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $16.97, for a total value of $3,176,156.11. Following the sale, the chief financial officer owned 177,461 shares in the company, valued at $3,011,513.17. This represents a 51.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 409,639 shares of company stock worth $7,233,399 over the last quarter. Insiders own 5.04% of the company’s stock.

Hedge Funds Weigh In On Relay Therapeutics

A number of institutional investors have recently added to or reduced their stakes in RLAY. Torren Management LLC purchased a new position in Relay Therapeutics during the fourth quarter valued at $30,000. KBC Group NV bought a new stake in shares of Relay Therapeutics during the 1st quarter valued at $34,000. Allworth Financial LP purchased a new stake in shares of Relay Therapeutics in the 2nd quarter worth about $34,000. Smartleaf Asset Management LLC grew its position in shares of Relay Therapeutics by 288.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock worth $37,000 after buying an additional 3,287 shares during the period. Finally, Caitong International Asset Management Co. Ltd bought a new position in shares of Relay Therapeutics in the 4th quarter worth about $46,000. Institutional investors own 96.98% of the company’s stock.

More Relay Therapeutics News

Here are the key news stories impacting Relay Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target to $29 from $28 and maintained a “Buy” rating. The target implies substantial potential upside from the $19.44 reference price, providing a positive valuation signal for RLAY. Benzinga
• Positive Sentiment: Zacks Research upgraded Relay Therapeutics from “Strong Sell” to “Hold.” Although not a bullish recommendation, the upgrade removes a strongly negative rating and may modestly improve investor sentiment. Zacks Research rating update
• Neutral Sentiment: HC Wainwright’s quarterly forecasts call for ongoing losses, ranging from $0.39 to $0.41 per share through 2027, while its FY2027 estimate is a $1.60-per-share loss. The firm nevertheless reiterated its Buy rating and $29 target, indicating that its thesis likely depends on future pipeline progress rather than near-term profitability. MarketBeat analyst estimates
• Negative Sentiment: HC Wainwright lowered its FY2026 EPS estimate to a $1.57 loss from a $1.50 loss and reduced its Q3 2026 estimate to a $0.37 loss from $0.36. Its Q4 estimate also fell to a $0.38 loss from $0.37, pointing to slightly weaker expected near-term results. MarketBeat forecast revisions
• Negative Sentiment: Relay Therapeutics’ latest reported quarter missed expectations, with EPS of negative $0.41 versus a consensus negative $0.39 and revenue of $0.35 million versus an expected $0.96 million. The shortfall may weigh on confidence in the company’s near-term execution. Relay Therapeutics Q2 results

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.